ライフサイエンスコーパス: epidermal growth factor

1 alpha (TNFalpha), interleukin (IL)-1beta, or epidermal growth factor.

2 TEN variants of MCF10a cells stimulated with epidermal growth factor.

3 s, resulting in additive effects of NHE1 and epidermal growth factor.

4 ls and identified a defect in endocytosis of epidermal growth factor.

5 estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormon

6 with hormone receptor-positive (HR+), human epidermal growth factor 2-positive (HER2+) disease.

7 n of epithelial cell sheets Stimulation with epidermal growth factor, a key morphogen, primarily incr

8 Epidermal growth factor, a kidney morphogen, increased d

9 Apoptotic neutrophils further release epidermal growth factor and promote the differentiation

10 The epidermal growth factor and the basic fibroblast growth

11 The presence of rigid epidermal growth factor domains in protein C as opposed

12 amin K-dependent clotting factors containing epidermal growth factor domains, such as factors VII, IX

13 ed with MDA-MB-231 cells expressing miR-149, epidermal growth factor (EGF) and amphiregulin expressio

14 individual compact quantum dots labeled with epidermal growth factor (EGF) and demonstrate the necess

15 g for two physiologically important ligands, epidermal growth factor (EGF) and hepatocyte growth fact

16 osine levels obtained after stimulation with epidermal growth factor (EGF) and that bicarbonate level

17 Moreover, epidermal growth factor (EGF) failed to suppress hepcidi

18 e crypt-villus axis and is the source of the epidermal growth factor (EGF) family member NEUREGULIN1

19 e effects of modulating GH through exogenous epidermal growth factor (EGF) in steatotic and nonsteato

20 In PC12 cells, epidermal growth factor (EGF) induces transient ERK acti

21 Epidermal growth factor (EGF) maintains intestinal stem

22 Reduced concentrations of epidermal growth factor (EGF) of maternal origin within

23 Systemic administration of epidermal growth factor (EGF) promoted HSC DNA repair an

24 cell equilibrium is feedback control of the epidermal growth factor (EGF) protease Rhomboid (Rho).

25 Activation of the epidermal growth factor (EGF) receptor (EGFR) at the cel

26 CD4 T cells express the epidermal growth factor (EGF) receptor ligand, heparin-b

27 It is well established that the epidermal growth factor (EGF) receptor, receptor tyrosin

28 rylated in vitro by the Tyr kinase domain of epidermal growth factor (EGF) receptor.

29 hat hypothesis and found that trafficking of epidermal growth factor (EGF) to late endosomes and degr

30 ted at tyrosine 4 and 31 upon stimulation by epidermal growth factor (EGF) to reduce the binding to a

31 We have found that epidermal growth factor (EGF) triggered an enrichment of

32 In contrast, epidermal growth factor (EGF) was significantly downregu

33 Upon addition of epidermal growth factor (EGF), both ESCRT-I and Vps4 are

34 IP)-10, monokine induced by IFN-gamma (MIG), epidermal growth factor (EGF), hepatocyte growth factor

35 As examples, Gaussia Luciferase (GLuc), epidermal growth factor (EGF), transforming growth facto

36 riant transcription factor 5 (ETV5) mediates epidermal growth factor (EGF)-induced hTERT expression i

37 ys, we investigated the role of PLCdelta4 in epidermal growth factor (EGF)-induced nuclear Ca(2+) sig

38 estigate the molecular mechanism, we utilize epidermal growth factor (EGF)-inducible immediate early

39 his site was predicted to separate the first epidermal growth factor (EGF)-like domain from the remai

40 rface protein 1 paralog (PvMSP1P), which has epidermal growth factor (EGF)-like domains, was identifi

41 In this study, we investigated the role of epidermal growth factor (EGF)-like repeats and discoidin

42 Nevertheless, all EGFR isoforms bind the epidermal growth factor (EGF).

43 iate with gene expression changes, including epidermal growth factor (EGF).

44 ll as in animals following overexpression of epidermal growth factor (EGF).

45 transforming growth factor-beta [TGF-beta1], epidermal growth factor [EGF], platelet-derived growth f

46 enrichment of phosphoproteins related to the epidermal growth factor (EGFR)/ERK pathway in SORLA tran

47 Infusion of epidermal growth factor enabled stalled striatal astrocy

48 and this effect was associated with reduced epidermal growth factor expression and mammalian target

49 -me signals, such as Mfge8 (milk fat globule-epidermal growth factor factor 8), and reduced capacity

50 ancient and similarly sized domains, such as Epidermal Growth Factor, Fibronectin Type 3, Immunoglobu

51 l formulation was loaded with peptide, human epidermal growth factor (HEGF), coupled to a chelator fo

52 Here, we show that the VACV epidermal growth factor homologue, VGF, promotes infecte

53 yrosine kinase with immunoglobulin-like loop epidermal growth factor homology domain 2, vascular endo

54 yrosine kinase with immunoglobulin-like loop epidermal growth factor homology domain 2, vascular endo

55 We analysed internalization of epidermal growth factor in patient cells and identified

56 decreased EGFR degradation when activated by epidermal growth factor, increased EGFR protein expressi

57 Importantly, Ras activation by epidermal growth factor is not altered when IQGAP1 or IQ

58 normalized circulating insulin, leptin, and epidermal growth factor levels.

59 selectivity of ADAM17 toward Heparin-binding epidermal growth factor like growth factor (HB-EGF), a c

60 Epidermal Growth Factor Like-domain 7 (EGFL7), firstly d

61 dominantly composed of eight calcium-binding epidermal growth factor-like (cbEGF) domains, each of wh

62 In this study, we demonstrate that epidermal growth factor-like 9 (EGFL9) is significantly

63 nal hydroxylation of Asp and Asn residues in epidermal growth factor-like domains (EGFDs).

64 ion of asparaginyl- and aspartyl-residues in epidermal growth factor-like domains (EGFDs).

65 ses the hydroxylation of Asp/Asn-residues in epidermal growth factor-like domains (EGFDs).

66 y demonstrated that upregulation of multiple epidermal growth factor-like domains 11 (MEGF11) gene ex

67 cacy of locally administered heparin-binding epidermal growth factor-like growth factor (HB-EGF), a p

68 eceptor (EGFR) ligand HBEGF (heparin-binding epidermal growth factor-like growth factor) and a consti

69 nstrate that a testicular germ-cell-secreted epidermal growth factor-like protein, neural epidermal g

70 epidermal growth factor-like protein, neural epidermal growth factor-like-like 2 (NELL2), specificall

71 The photopatterned epidermal growth factor presentation is exploited to pro

72 as been implicated as an oncogenic driver in epidermal growth factor receptor ( EGFR)-mutant non-smal

73 The resultant anti-epidermal growth factor receptor (anti-EGFR) AEC worked

74 Here, a six-arginine-tailed anti-epidermal growth factor receptor (EGFR) affibody was emp

75 Epidermal growth factor receptor (EGFR) and human epider

76 B and gH directly bind and activate cellular epidermal growth factor receptor (EGFR) and integrin bet

77 Epidermal growth factor receptor (EGFR) and its downstre

78 transcripts coding for oncoproteins such as epidermal growth factor receptor (EGFR) and MYC can supp

79 phosphorylation of the known PTPRJ substrate epidermal growth factor receptor (EGFR) and of other dow

80 t FCHSD2 loss impacts recycling of the RTKs, epidermal growth factor receptor (EGFR) and proto-oncoge

81 We apply this model to epidermal growth factor receptor (EGFR) antibodies and f

82 The inhibitory epidermal growth factor receptor (EGFR) antibody, cetuxi

83 g cancer (NSCLC) patient samples, where anti-epidermal growth factor receptor (EGFR) assisted platfor

84 Constitutive activation of the epidermal growth factor receptor (EGFR) because of somat

85 For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many col

86 tyrosine kinases, including signaling by the epidermal growth factor receptor (EGFR) family (EGFR1-4

87 tor Dynamics (TReD), studied the dynamics of epidermal growth factor receptor (EGFR) in seven breast

88 qualitative and quantitative analyses of the epidermal growth factor receptor (EGFR) in tissues, we g

89 identified that the combination of afatinib (epidermal growth factor receptor (EGFR) inhibitor) and Y

90 Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in ad

91 S-mutated colorectal cancers unresponsive to epidermal growth factor receptor (EGFR) inhibitors.

92 Epidermal growth factor receptor (EGFR) is a critical re

93 Mutational activation of the epidermal growth factor receptor (EGFR) is a major playe

94 The epidermal growth factor receptor (EGFR) is a major regul

95 Epidermal growth factor receptor (EGFR) is a prototype r

96 Epidermal growth factor receptor (EGFR) is commonly over

97 Asymmetric dimer formation of epidermal growth factor receptor (EGFR) is crucial for E

98 We demonstrate that the epidermal growth factor receptor (EGFR) is required as a

99 a specific tyrosine residue in STING by the epidermal growth factor receptor (EGFR) is required for

100 dentify such gain-of-function mutants in the epidermal growth factor receptor (EGFR) kinase.

101 Transgenic mice (HBUS) that express the epidermal growth factor receptor (EGFR) ligand HBEGF (he

102 cription of both antioxidant enzymes and the epidermal growth factor receptor (EGFR) ligand, amphireg

103 Here, we demonstrate that epidermal growth factor receptor (EGFR) ligands can acti

104 In epidermal growth factor receptor (EGFR) mutant non-small

105 Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small

106 The discovery of activating epidermal growth factor receptor (EGFR) mutations spurre

107 r proportion of adenocarcinoma histology and epidermal growth factor receptor (EGFR) mutations.

108 ) affects PPIN structure and function of the Epidermal Growth Factor Receptor (EGFR) network in color

109 ting NK cell receptor NKp30 on NK cells with epidermal growth factor receptor (EGFR) on tumor cells i

110 Overexpression of the epidermal growth factor receptor (EGFR) on various cance

111 by activating mutations in the gene encoding epidermal growth factor receptor (EGFR) or rearrangement

112 rized by mutually exclusive mutations in the epidermal growth factor receptor (EGFR) or the guanosine

113 can be mediated by different factors such as epidermal growth factor receptor (EGFR) overexpression a

114 in phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR) pathway genes ar

115 In the posterior, JAK/STAT works with the epidermal growth factor receptor (EGFR) pathway to expre

116 Differential epidermal growth factor receptor (EGFR) phosphorylation

117 nd which, in turn, inhibits synthesis of the epidermal growth factor receptor (EGFR) protein.

118 We report that epidermal growth factor receptor (EGFR) regulates DNA re

119 The epidermal growth factor receptor (EGFR) signaling cascad

120 For instance, targeting epidermal growth factor receptor (EGFR) signaling is eff

121 Epidermal growth factor receptor (EGFR) signaling is ess

122 Epidermal growth factor receptor (EGFR) signaling is ini

123 cleotide oligomerization domain 2 (NOD2) and epidermal growth factor receptor (EGFR) signaling pathwa

124 tome of RIS and discovered that genes of the epidermal growth factor receptor (EGFR) signaling pathwa

125 a-cell proliferation in rats is dependent on epidermal growth factor receptor (EGFR) signaling.

126 severe pancreatitis with hyperactivation of epidermal growth factor receptor (EGFR) signaling.

127 Falpha), interleukin 6 receptor (IL-6R), and epidermal growth factor receptor (EGFR) signaling.

128 xcitable reaction-diffusion system involving epidermal growth factor receptor (EGFR) signalling inter

129 utilized a library of 7,216 randomly mutated epidermal growth factor receptor (EGFR) single-nucleotid

130 e previously demonstrated that inhibition of epidermal growth factor receptor (EGFR) slowed corneal e

131 proliferation in vitro, and was dependent on epidermal growth factor receptor (EGFR) stimulation.

132 Epidermal growth factor receptor (EGFR) targeted therapi

133 overy and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic anti

134 e suggested that acquired resistance to anti-epidermal growth factor receptor (EGFR) therapies such a

135 Targeting epidermal growth factor receptor (EGFR) through an allos

136 ating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase

137 Several epidermal growth factor receptor (EGFR) tyrosine kinase

138 I's role in EMT, we examined the activity of epidermal growth factor receptor (EGFR), a known EMT dri

139 In comparison to epidermal growth factor receptor (EGFR), a well-establis

140 kinases (RTKs) on host cells, including the epidermal growth factor receptor (EGFR), and activates c

141 lecule (EpCAM), carbonic anhydrase IX (CA9), epidermal growth factor receptor (EGFR), and hepatocyte

142 RTK hepatocyte growth factor receptor (MET), epidermal growth factor receptor (EGFR), and human epide

143 ng to integrin alpha5beta1, alphavbeta1, and epidermal growth factor receptor (EGFR), and subsequent

144 Nuclear RTKs, including the epidermal growth factor receptor (EGFR), are important f

145 Receptor tyrosine kinases (RTKs), MET and epidermal growth factor receptor (EGFR), are known to pl

146 Inhibition of epidermal growth factor receptor (EGFR), extracellular s

147 eceptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR), locally increas

148 iated binding of 7D12 mutants to its target, epidermal growth factor receptor (EGFR), on the surface

149 rs through a signaling cascade that includes epidermal growth factor receptor (EGFR), signal transduc

150 t evidence that in NSCs Chi3l3 activates the epidermal growth factor receptor (EGFR), thereby inducin

151 of argos (aos), an inhibitory ligand to the epidermal growth factor receptor (EGFR), to fine-tune th

152 such as poly (ADP-ribose) polymerase (PARP), epidermal growth factor receptor (EGFR), Vascular endoth

153 The epidermal growth factor receptor (EGFR), when carrying a

154 response to growth factor binding stimulus, epidermal growth factor receptor (EGFR), which is physio

155 ty specifically in cells over-expressing the epidermal growth factor receptor (EGFR), with over 99% r

156 gnificant attenuation of the pro-tumorigenic Epidermal Growth Factor Receptor (EGFR)-Akt axis, and fi

157 ced non-small-cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR)-directed oral ty

158 nsformation in a Drosophila genetic model of epidermal growth factor receptor (EGFR)-driven tumorigen

159 ed the heterointeractions of nine RTK pairs, epidermal growth factor receptor (EGFR)-EPH receptor A2

160 monstrated a connection that upregulation of epidermal growth factor receptor (EGFR)-leukemia inhibit

161 ade radiation-mediated apoptosis by p53- and epidermal growth factor receptor (EGFR)-mediated DNA rep

162 Here, we show that GP78 is required for epidermal growth factor receptor (EGFR)-mediated ERK act

163 In epidermal growth factor receptor (EGFR)-mutant lung aden

164 Epidermal growth factor receptor (EGFR)-targeted therapy

165 atient glioblastoma samples before and after epidermal growth factor receptor (EGFR)-targeted therapy

166 entry include the tetraspanin CD151 and the epidermal growth factor receptor (EGFR).

167 d cells, which, in turn, is regulated by the epidermal growth factor receptor (EGFR).

168 ISCs, including Cbl, a negative regulator of Epidermal Growth Factor Receptor (EGFR).

169 been used to measure phosphorylation of the epidermal growth factor receptor (EGFR).

170 utic strategy for tumours overexpressing the epidermal growth factor receptor (EGFR).

171 es to enhancing KSHV infectivity through the epidermal growth factor receptor (EGFR).

172 also depended on the transactivation of the epidermal growth factor receptor (EGFR).

173 model antibody cetuximab and its target, the epidermal growth factor receptor (EGFR).

174 We found that epidermal growth factor receptor (EGFR)/BRAF inhibition

175 ERBB4 is a member of the epidermal growth factor receptor (EGFR)/ERBB subfamily o

176 ven inflammation, we identify a role for the epidermal growth factor receptor (EGFR/ERBB1) as a media

177 The human epidermal growth factor receptor (EGFR/ERBB1) is a recep

178 ven with traditional chemical and anti-human epidermal growth factor receptor (HER) treatments.

179 ollows: luminal A-like, luminal B-like human epidermal growth factor receptor (HER)2-negative/HER2-po

180 In this immuno-PET study of the anti-human epidermal growth factor receptor (HER3) mAb GSK2849330,

181 ead and neck squamous cell cancer, the human epidermal growth factor receptor 1 (EGFR) is the dominan

182 The most upregulated protein was human epidermal growth factor receptor 2 (ERBB2/HER2), which i

183 ion in estrogen receptor (ER)-positive human epidermal growth factor receptor 2 (HER(2))-negative bre

184 01 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) -targeting dru

185 mal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2) are involved i

186 Amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2) are observed i

187 (ERalpha), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is

188 eptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is

189 Overexpression of human epidermal growth factor receptor 2 (HER2) in breast canc

190 rosine kinase inhibitor neratinib is a human epidermal growth factor receptor 2 (HER2) inhibitor appr

191 Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors inv

192 Human epidermal growth factor receptor 2 (HER2) is overexpress

193 Overexpression of the human epidermal growth factor receptor 2 (HER2) is the cause o

194 Human epidermal growth factor receptor 2 (HER2) is used as a t

195 Data on human epidermal growth factor receptor 2 (HER2) oncogene overe

196 esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive.

197 r (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are absent is

198 Patients are categorized by human epidermal growth factor receptor 2 (HER2), hormone recep

199 stinct treatment with agents targeting human epidermal growth factor receptor 2 (HER2), specifically

200 Human epidermal growth factor receptor 2 (HER2)-amplified brea

201 Here, we transiently expressed human epidermal growth factor receptor 2 (HER2)-binding monome

202 The TEXT/SOFT HR-positive/human epidermal growth factor receptor 2 (HER2)-negative analy

203 (AC) in BRCA carriers with stage I-III human epidermal growth factor receptor 2 (HER2)-negative breas

204 Estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative cases

205 RPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metas

206 germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metas

207 tors for hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative metas

208 Methods: Patients with ER+/human epidermal growth factor receptor 2 (HER2)-negative metas

209 T (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)-negative, carc

210 Patients with human epidermal growth factor receptor 2 (HER2)-positive BC re

211 dress treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breas

212 dence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breas

213 In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breas

214 NE trial, patients with stage I to III human epidermal growth factor receptor 2 (HER2)-positive breas

215 Patients with human epidermal growth factor receptor 2 (HER2)-positive metas

216 -drug conjugates (ADCs) containing the human epidermal growth factor receptor 2 (HER2)-specific antib

217 Conclusion Human epidermal growth factor receptor 2 (HER2)-targeted imagi

218 Background Human epidermal growth factor receptor 2 (HER2)-targeted thera

219 Although human epidermal growth factor receptor 2 (HER2)-targeted thera

220 ast cancer cells that are positive for human epidermal growth factor receptor 2 (HER2).

221 sly with two different epitopes of the human epidermal growth factor receptor 2 (HER2).

222 lecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERB

223 labeled forms of EGFR and its paralog, human epidermal growth factor receptor 2 (HER2/ERBB2) in vesic

224 analyzed a cohort of 156 patients with human epidermal growth factor receptor 2 -negative breast canc

225 Injection site and the tumor markers human epidermal growth factor receptor 2 and estrogen receptor

226 While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) bre

227 ition, a number of biomarkers, such as human epidermal growth factor receptor 2 protein, p53 tumor su

228 en receptor, progesterone receptor and human epidermal growth factor receptor 2 status and tumor grad

229 both positive for ER and negative for human epidermal growth factor receptor 2, each with characteri

230 en receptors and do not have amplified human epidermal growth factor receptor 2, the main therapeutic

231 e, NSG, and humanized NSG mice bearing human epidermal growth factor receptor 2-expressing human brea

232 e estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) brea

233 rogesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breast cance

234 mide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast

235 s of TC is an effective/safe option in human epidermal growth factor receptor 2-negative EBC with pN0

236 women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, and node-ne

237 women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, axillary no

238 001) than those of triple-negative and human epidermal growth factor receptor 2-positive (HER2+) canc

239 reast cancers from triple-negative and human epidermal growth factor receptor 2-positive cancers.

240 d in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative

241 Human epidermal growth factor receptor 2-positive tumors were

242 n-Like Growth Factor Receptor 1 (IGF-1R) and Epidermal Growth Factor Receptor 3 (ErbB3) have been imp

243 rmal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) have been inve

244 n-to-treat wild-type patients (patients with epidermal growth factor receptor [EGFR] or anaplastic ly

245 ned in its active, drug-insensitive state by epidermal growth factor receptor and aurora kinase signa

246 ly show that p-Ezrin (T567) is controlled by epidermal growth factor receptor and MET.

247 high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family ki

248 udies demonstrated that YAP1 interacted with epidermal growth factor receptor and TGF-beta signaling

249 used to uncover the oligomeric states of the epidermal growth factor receptor and the secretin recept

250 For example, we confirm Epidermal Growth Factor Receptor elevation and Phosphata

251 Epidermal growth factor receptor I (EGFR) is overexpress

252 T-I complex formation and the degradation of epidermal growth factor receptor in the multivesicular b

253 Cetuximab, an epidermal growth factor receptor inhibitor, has been pro

254 Lapatinib, an approved epidermal growth factor receptor inhibitor, was explored

255 The epidermal growth factor receptor ligand Amphiregulin has

256 cell migration by an indirect activation of epidermal growth factor receptor mediated by metalloprot

257 ly to patients without driver alterations in epidermal growth factor receptor or ALK.

258 nt inhibitors of protein kinases such as the epidermal growth factor receptor or Bruton's tyrosine ki

259 nbasal, according to cytokeratins 5/6 and/or epidermal growth factor receptor positivity by immunohis

260 ell and cell-extracellular matrix signaling, epidermal growth factor receptor signaling, and Rho-GTPa

261 upregulation of effector pathways including epidermal growth factor receptor signaling, extracellula

262 target epigen and a concomitant increase in epidermal growth factor receptor signaling.

263 FF2) acts via chemokine C-X-C receptor 4 and epidermal growth factor receptor signalling, including e

264 ry identified EHD1 (Eps15 [endocytic adaptor epidermal growth factor receptor substrate 15] homology

265 ging as biomarkers of acquired resistance to Epidermal Growth Factor Receptor therapy.

266 Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2) expressio

267 Trastuzumab is highly effective for human epidermal growth factor receptor type 2 (HER2)-positive

268 (131)I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a

269 es (ie, type, grade, hormone receptor, human epidermal growth factor receptor type 2/neu, Ki-67) were

270 f AM in the treatment of advanced progressed epidermal growth factor receptor tyrosine kinase inhibit

271 d-generation, CNS-active, irreversible, oral epidermal growth factor receptor tyrosine kinase inhibit

272 The oncogene epidermal growth factor receptor variant III (EGFRvIII)

273 Expression of insulin receptor and epidermal growth factor receptor was reduced in hippocam

274 e toward the inhibition of its family member epidermal growth factor receptor with small-molecule inh

275 Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non-small cell

276 eceptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the

277 i ASPP2 signaling by inhibitors of the EGFR (epidermal growth factor receptor) signaling pathway-iden

278 protein abundance of caveolin-1, dystrophin, epidermal growth factor receptor, and insulin receptor-b

279 evant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed de

280 targets in corticotroph adenomas include the epidermal growth factor receptor, cyclin-dependent kinas

281 ules in the injured kidney, including Smad3, epidermal growth factor receptor, platelet-derived growt

282 (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) are the three

283 (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status.

284 vides significant clinical benefit for human epidermal growth factor receptor-2 (HER2)-positive breas

285 -glucan exposure, activated the Dectin-1-SYK-epidermal growth factor receptor-AKT/extracellular signa

286 latin with cetuximab-an antibody against the epidermal growth factor receptor-can preserve high survi

287 B (ERBB)3 as an essential protein kinase in epidermal growth factor receptor-dependent head and neck

288 ur results demonstrate how poxviruses hijack epidermal growth factor receptor-induced cell motility t

289 oss of RHAMM function or expression promoted epidermal growth factor receptor-regulated MMP-9 express

290 ) were analyzed to map the safety profile of epidermal growth factor receptor-tyrosine kinase inhibit

291 ted sphingosine kinase 1, S1P receptor 2 and epidermal growth factor receptor.

292 ting loci has been characterized as a mutant epidermal growth factor receptor.

293 oliferation by downregulating the E-cadherin/epidermal growth factor receptor/mitogen-activated prote

294 32 has been detected after activation of the epidermal growth factor receptor; however, the specific

295 nding lectin]; and 3 with lower risk: ErbB1 [epidermal growth factor receptor], GDF-11/8 [growth diff

296 superassemblies are surface-engineered with epidermal growth factor receptors and can be targeted to

297 arylaminoquinazoline moiety with affinity to epidermal growth factor receptors, and a hydrophilic bet

298 Delta and notch-like epidermal growth factor-related receptor (DNER) had the

299 ctivated Rac1 in membrane ruffles induced by epidermal growth factor stimulation.

300 Interleukin-17 and epidermal growth factor were identified as important inf